Human Growth Hormone Market
Number of pages: 100 | Report Format: PDF | Published date: April 28, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 4.4 billion |
|
Revenue Forecast in 2031 |
US$ 9.1 billion |
|
CAGR |
8.4% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Indication, Route of Administration, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global human growth hormone market was valued at US$ 4.4 billion and is expected to register a revenue CAGR of 8.4% to reach US$ 9.1 billion in 2031.
Human Growth Hormone Market Fundamentals
Human growth hormone (HGH) plays a vital role in promoting growth and development in children. Also, it helps regulate body composition, muscle and bone growth, and metabolism in children and adults. Excessive secretion of growth hormones and deficiency are linked to several diseases. Growth failure in children and a decline in bone density and muscular mass in adults are consequences of growth hormone deficiency. Contrarily, excess growth hormone can lead to acromegaly or gigantism, conditions marked by uncontrollable bone and tissue growth. Human growth hormone treatment is a medical therapy that uses synthetic human growth hormone to treat various conditions related to growth hormone disorders. This treatment can help children with growth hormone deficiency or other conditions affecting their growth. It can also treat adults with growth hormone deficiency caused by pituitary tumors or other medical conditions.
Currently, researchers are concentrating on many novel growth hormone treatment areas due to increased research and development efforts to improve treatments. Creating longer-acting formulations, experimenting with novel delivery systems such as nasal sprays, and examining the possible advantages of mixing growth hormones with other hormones or drugs are a few of these aspects. Researchers are also investigating how growth hormones can treat ailments other than growth abnormalities, like metabolic problems and age-related muscle loss. Long-acting growth hormone formulations have been developed to reduce the frequency of injections required for patients. These formulations effectively maintain growth hormone levels and improve patient adherence to treatment.
Additionally, combination therapy with growth hormones and other hormones such as insulin-like growth factor 1 (IGF-1) or gonadotropins may improve treatment outcomes for certain patients. This approach has shown promising results in patients with growth hormone deficiency, Turner syndrome, and other conditions. However, further research is needed to determine the optimal dosages and duration of combination therapy.
[89]
Human Growth Hormone Market Dynamics
The incidence of growth hormone deficiency (GHD) is increasing globally, particularly among children. This is one of the primary factors driving the human growth hormone market growth. The prevalence of growth hormone deficiency varies depending on the population studied and the diagnostic criteria used. However, according to the article published by the National Institutes of Health, it is estimated that growth hormone deficiency affects approximately 1 in 3,500 to 1 in 10,000 children. In adults, the prevalence is estimated to be between 1 in 100 and 1 in 1,000, although this may be underestimated due to under diagnosis.
Athletes and bodybuilders sometimes use growth hormone (GH) to enhance performance and build muscle. When used in sports and fitness, GH is typically administered by injection. It is believed to promote muscle growth by stimulating the production of insulin-like growth factor 1 (IGF-1), an important hormone for muscle and bone growth. GH is also thought to increase the body's ability to burn fat and improve recovery after exercise. The rising popularity of sports and fitness activities drives the demand for human growth hormones. Human growth hormone supplements are promoted to increase muscle growth and athletic performance, which appeals to people who want to reach their fitness goals as soon and efficiently as possible. Moreover, the increased demand for personalized medicines is another factor to drive the growth hormone market growth. As people become more health conscious, the demand for human growth hormone supplements is expected to rise. Additionally, the growing awareness about the benefits of HGH in anti-aging treatments is also contributing to the market's growth.
Furthermore, the technological advances and improvements in drug delivery systems significantly contributed to the human growth hormone market growth. New delivery devices, such as needle-free injection systems and pen devices with built-in dose memory, can improve patient compliance and ease of use. After receiving the appropriate instruction, patients can administer both cool. clickTM and Zomajet by themselves, which may increase patient compliance with therapy. Also, gene therapy using recombinant DNA technology to deliver the growth hormone gene has shown promising results in preclinical studies. It may offer a more permanent solution for patients with growth.
However, human growth hormone therapy is expensive, and many patients may be unable to afford it. This can limit access to treatment, particularly in developing countries where healthcare resources may be limited. Growth hormone treatment has some potential side effects, such as the possibility of developing diabetes, hypertension, and acromegaly, even though it is normally safe when administered under the guidance of a medical practitioner. These safety worries may constrain the use of human growth hormones in some patient populations. People with a history of cancer or other illnesses may not be ideal candidates for human growth hormone treatment. People with a family history of diabetes or high blood pressure may need to have their therapy thoroughly monitored. Furthermore, The market is seeing the introduction of biosimilar versions of various growth hormone drugs as their patents expire.
Human Growth Hormone Market Ecosystem
This report provides the global human growth hormone market analysis regarding revenue, market growth, market dynamics, regional landscape, and overall competitive positioning of the major market players. The global human growth hormone market overview is analyzed from the following perspectives: indication, route of administration, distribution channel, and region.
Human Growth Hormone Market by Indication
[90]
Based on the indication, the global human growth hormone market is segmented into growth hormone deficiency, turner syndrome, idiopathic short stature, Prader-Willi syndrome, and others.
Growth hormone deficiency accounted for the largest revenue share of the global human growth hormone market in 2022. Growth hormone deficiency is the primary and most prevalent indication for human growth hormone treatment. Short stature, delayed puberty, decreased muscle mass, and a loss of bone density are just a few symptoms that can result from growth hormone deficiency, which is caused when the pituitary gland produces insufficient growth hormone. Human growth hormone is used to treat low levels of growth hormone and enhance development and growth in those who are affected. Children are frequently diagnosed with growth hormones, and early detection and therapy are crucial for optimum growth and development. This indicates that many GHD patients need long-term human growth hormone therapy, which causes a persistent need for growth hormone supplies.
Human Growth Hormone Market by Route of Administration
Based on the route of administration, the global human growth hormone market is segmented into parenteral and oral.
The parenteral segment accounted for the largest revenue share of the global human growth hormone market in 2022. Studies have demonstrated that the intramuscular (IM) parenteral route of administration is efficient for delivering human growth hormone therapy and can enhance growth and development in those with growth hormone insufficiency. Since the intramuscular route of administration is a straightforward and practical way to provide growth hormones, it may increase patient compliance. This can lessen the chance of problems and improve treatment results. Widespread availability and production by various manufacturers of growth hormone products have contributed to the popularity of this mode of administration among patients and medical professionals.
Human Growth Hormone Market by Distribution Channel
Based on the distribution channels, the global human growth hormone market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies accounted for a significant revenue share of the global human growth hormone market in 2022. Hospital pharmacies have played a significant part in the distribution of human growth hormone products, contributing significantly to the global human growth hormone market. This is primarily because they can provide long-term human growth hormone therapy to individuals with serious or chronic medical disorders, including growth hormone deficiency. Hospital pharmacies have the knowledge and facilities to handle the unique handling and storage needs of human growth hormone medicines. They also link closely to the medical professionals overseeing human growth hormone treatments in hospitals. Hospital pharmacies are and will continue to be a key distribution channel for human growth hormone products because of these characteristics and their proficiency in navigating insurance coverage constraints.
Human Growth Hormone Market by Region
Based on the region, the global human growth hormone market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global human growth hormone market in 2022. As a result of the region's huge patient population suffering from illnesses associated with growth hormone deficiency. Both children and adults in this demographic need this hormonal therapy for growth and the treatment of other disorders, such as Turner syndrome and Prader-Willi syndrome. Additionally, the region has a developed healthcare system with a high diagnosis and understanding of these problems, influencing the market's high demand for human growth hormone products. Additionally, many pharmaceutical and biotech firms in North America focus on producing human growth hormone drugs. These businesses have made significant research and development investments to enhance efficacy, security, and human growth hormone therapy delivery strategies. To guarantee that their products are broadly accessible to patients, they have also built extensive distribution networks, including collaborations with hospitals, clinics, and specialized pharmacies. As a result, human growth hormones are now more widely available in this region.
Human Growth Hormone Market Competitive Landscape
Multiple companies across the globe are investing in raising awareness and reimbursement, which is expected to improve the human growth hormone market outlook. Notable market participants account for the largest revenue share of the global human growth hormone market include,
Human Growth Hormone Market Strategic Developments
Human growth hormone is a peptide hormone that stimulates growth, cell reproduction, and cell regeneration in humans.
Growth hormone deficiency accounted for the largest revenue share of the global human growth hormone market.
The increasing prevalence of growth hormone deficiency is the major driving factor for global human growth hormone market growth.
Key companies operating the global human growth hormone market are AnkeBio Co. Ltd, Eli Lilly and Company, EMD Serono Inc., Ipsen S.A., Merck KGaA, Novo Nordisk Inc., and Pfizer, Inc.
The global human growth hormone market is expected to grow at a revenue CAGR of 8.4% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain